EIN Presswire: Biotechnology Press Releases

Rosetta Genomics to Raise $6.6 Million in Registered Direct Offering

Thu, 24 May 2012 23:36:00 +0000

Rosetta Genomics Ltd. ("Rosetta") (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced it has entered into definitive agreements with investors to purchase an aggregate of 570,755 ordinary shares at a price of $11.50 per share in a registered direct offering. The offering is expected to close on or about May 31, 2012, subject to the satisfaction of customary closing conditions.

Rosetta plans to use the net proceeds from the offering primarily to fund its operations and for other general corporate purposes, including, but not limited to, repayment or refinancing of existing indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development and product development.

Aegis Capital Corp. acted as the exclusive placement agent for the offering.

A shelf registration statement relating to the securities offered and sold in the offering has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective. A final prospectus supplement relating to the offering will be filed by Rosetta with the SEC. Copies of the final prospectus supplement and accompanying prospectus may be obtained directly from Rosetta by contacting Rosetta Genomics Ltd., 10 Plaut Street, Science Park, Rehovot 76706, Israel or via telephone at 215-382-9000 ext. 309 or via e-mail at investors@rosettagenomics.com or from Aegis Capital Corp. by request to Prospectus Department, 810 Seventh Avenue, 11th Floor, New York, NY, 10019, telephone: 212-813-1010 or e-mail: prospectus@aegiscap.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's miRview product line is commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the expected closing of the offering, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2011 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact:
Rosetta Genomics
Ken Berlin
President & CEO
(215) 382-9000 ext. 326
investors@rosettagenomics.com

Investor Contacts:
LHA
Anne Marie Fields
(212) 738-3777
afields@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com

Royalty Pharma Raises $600 Million of Debt

Thu, 24 May 2012 23:02:00 +0000

Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, announced that it has successfully issued $600 million of incremental Term Loan B debt through RPI Finance Trust ("RPIFT"), bringing total debt outstanding at RPIFT to approximately $3.4 billion. Proceeds will be used to fund future acquisitions.

The new $600 million tranche was priced at 98.5 with a borrowing spread of Libor + 3.00% and matures on November 9, 2018, but otherwise has the same terms and conditions as RPIFT's existing Term Loan B facilities, which consist of a $850 million tranche maturing on November 9, 2016 with a borrowing spread of Libor + 2.75%; and a $1.9 billion tranche maturing on May 9, 2018 with a borrowing spread of Libor + 3.00%. The new tranche was very well received, with strong demand resulting in the issue size being increased from $500 million to $600 million. Upon issuance of the new debt, RPIFT continues to have a conservative leverage ratio (measured as total debt to EBITDA) of 3.5x, compared to 2.9x prior to issuance. All three rating agencies, Moody's Investor Service, Standard & Poor's and Fitch have affirmed RPIFT's investment grade ratings.

Pablo Legorreta, Founder & Chief Executive Officer, commented, "Overall, we are very pleased with the positive outcome of this transaction, especially in light of the current market conditions. We believe the robust execution and our ability to maintain the same borrowing spread underscores the strength of Royalty Pharma's reputation in the debt markets and the underlying high quality of our well diversified royalty portfolio. Despite the weak current market, from a long term perspective the overall cost of this debt financing is extremely attractive."

Susannah Gray, Executive Vice President and Chief Financial Officer, commented, "We appreciate the continued support of our existing lenders and welcome the new lenders to our borrowing group. We believe our ability to place this additional debt demonstrates our lenders confidence in Royalty Pharma's credit profile."

Bank of America Merrill Lynch acted as lead book runner. Goldman Sachs and Citigroup acted as joint-book runners. Davis Polk & Wardwell acted as legal advisor to Royalty Pharma.

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products. With over $7.5 billion in assets, including royalty assets of $7 billion, the company owns royalty interests in over 30 marketed and late stage biopharmaceutical products. Leading products in Royalty Pharma's portfolio include: Abbott's Humira®, Johnson and Johnson's Remicade® and Prezista®, Gilead's Atripla®, Truvada®, Complera® and Emtriva®, Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, Genentech's Rituxan®, Forest's Savella®, Astella's Lexiscan®, Merck's Januvia/Janumet®, Roche and UCB's Cimzia® and Mircera®. The company has a fifteen year history of providing value to holders of royalty interests, including its $700 million acquisition of AstraZeneca's Humira® royalty, its $700 million purchase of a portion of Northwestern University's Lyrica® royalty, its $650 million purchase of New York University's Remicade® royalty, its joint $525 million acquisition with Gilead Sciences of Emory University's emtricitabine royalty interests, its $609 million acquisition of Astellas' DPP-IV patent estate and associated royalty interests, and its $761 million acquisition of an interest in the amounts payable to the former shareholders of Fumapharm on Biogen Idec's BG-12.

Royalty Pharma
RP Management LLC
Investor Relations
+ 1 (212) 883-0200
Email Contact

Court Orders Dismissal of CUROSURF(R) Case

Thu, 24 May 2012 22:10:00 +0000

Cornerstone Therapeutics Inc. (NASDAQ: CRTX) today announced that on May 18, 2012 the United States District Court for the Western District of New York issued a decision and order granting Cornerstone's motion to dismiss all the claims of ONY, Inc. in the case filed by ONY. The case concerned Cornerstone's neonatal lung surfactant, CUROSURF.

ONY, the maker of a competing neonatal lung surfactant, had filed suit on December 2, 2011 in connection with an article appearing in the September 1st 2011 online issue of the Journal of Perinatology. The article was based on a retrospective study in infants with Respiratory Distress Syndrome (RDS) that concluded that CUROSURF was associated with a significantly reduced likelihood of death when compared with ONY's product. ONY alleged that the conclusions of the article were unreliable and misleading. The Court ruled that the article was not misleading with respect to the facts on which it was based, and dismissed ONY's claims against Cornerstone and all the other named defendants.

About CUROSURF

CUROSURF (poractant alfa) is an intratracheal suspension indicated for the treatment (rescue) of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Important Safety Information

CUROSURF is intended for intratracheal use only. THE ADMINISTRATION OF EXOGENOUS SURFACTANTS, INCLUDING CUROSURF, CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified in response to respiratory changes. CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants. TRANSIENT ADVERSE EFFECTS SEEN WITH THE ADMINISTRATION OF CUROSURF INCLUDE BRADYCARDIA, HYPOTENSION, ENDOTRACHAEL TUBE BLOCKAGE, AND OXYGEN DESATURATION. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring. Please see full prescribing information at www.curosurf.com.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (NASDAQ: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on commercializing products for the hospital, niche respiratory and related specialty markets. Key elements of the Company's strategy are to focus its commercial and internal development efforts in the hospital and related specialty product sector within the U.S. pharmaceutical marketplace; continue to seek out opportunities to acquire companies and marketed and/or registration-stage products that fit within the Company's focus areas; and generate revenues by marketing approved generic products through the Company's wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. For more information, visit www.crtx.com.

TRADEMARKS
CUROSURF® is owned by Chiesi Farmaceutici S.p.A. and is licensed to Cornerstone Therapeutics for sales and marketing purposes in the United States.

Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovion's Brovana® Product

Thu, 24 May 2012 21:33:56 +0000

Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovion's Brovana® Product

PR Newswire

PITTSBURGH, May 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Mylan Specialty L.P., f/k/a Dey Pharma, L.P., has entered into an agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor Inc., to resolve the parties' patent litigation relating to Sunovion's Brovana® product.

The U.S. District Court for the Southern District of New York's Final Judgment and Order notes that the parties have entered into a settlement and license agreement and that Sunovion has acknowledged that two Mylan patents are valid, enforceable and infringed by Sunovion's Brovana® product. These patents expire on June 22, 2021. The terms of the parties' agreement are confidential.

Mylan CEO Heather Bresch commented, "We are pleased with this settlement and remain confident in the intellectual property protecting Perforomist®, as well as our combination product for the treatment of Chronic Obstructive Pulmonary Disease (COPD), currently in development. We believe this settlement and judgment by the Court further strengthen the potential of our Specialty franchise and its portfolio of products."

Mylan intends to appeal the judgment concerning other Mylan patents that were litigated.

This press release includes statements that constitute "forward-looking statements," including with regard to the settlement of the litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product sales; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.

Peers Underscored As An Effective Counseling Tool

Thu, 24 May 2012 20:23:10 +0000

Peers Underscored As An Effective Counseling Tool

State Independent Living Council Draws Eye Toward Peer-to-Peer Counseling During Mental Health Awareness Month

PR Newswire

SACRAMENTO, Calif., May 24, 2012 /PRNewswire/ -- With approximately one in four adults suffering from a diagnosable mental health disorder, coupled with restrictive funding and high case loads, the value of independent living centers (ILCs) providing peer-to-peer counseling is vital to effective mental health services. ILCs are generally thought of as resource centers solely for people with physical disabilities, but across the country, directors and staff at hundreds of centers identify themselves as people with mental health disabilities. These peers provide support for others coming to the ILCs.

"With May being Mental Health Awareness Month, this is the perfect time to highlight the union of independent living and mental health," said California State Independent Living Council Executive Director Liz Pazdral. "It's a given that people with shared experiences can relate better to one another and provide support from a place of authentic empathy. And it's often the practical advice resulting from peer support that helps a person rebuild his or her sense of community after a disconnecting experience."

Peer support started from people uniting to eliminate over-medication, coercion and human rights' violations of those living with mental illness. During the 1980s, acceptance of peer-delivered services in mental health grew, but little scientific evidence supported the trend. Beginning in 1988, the federal government funded research that produced evidence indicating peer-led services increased the social skills, decreased inpatient services and improved the self-confidence of consumers (sometimes known as survivors). By the late 1990s, the effectiveness of peer counseling was much more widely accepted.

In California, the Mental Health Services Act (MHSA) was passed in 2004 and mandated funds to operationalize peer-to-peer strategies "to promote consumer-operated services as well as the employment of mental health consumers in the mental health system."

But even before MHSA passed, ILCs in California were making strides forward. Communities Actively Living Independent & Free, Independent Living Center of Kern County, Independent Living Resource Center serving Central California, Independent Living Resource Center San Francisco (ILRCSF), Silicon Valley Independent Living Center and Westside Center for Independent Living (WCIL) were building reputations for providing strong mental health peer support. ILRC-SF and WCIL were tapped nationally to train and provide education on peer counseling for people with mental health disabilities to all independent living centers.

According to Pazdral, "Peer-to-peer action is powerful within mental health services, integral to independent living and a political badge of pride for the network of statewide independent living centers."

The California State Independent Living Council is an independent state agency which, in cooperation with the California State Department of Rehabilitation, prepares and monitors the State Plan for Independent Living. SILC solicits continual public feedback on the effectiveness of independent living services and coordinates with similar agencies and councils at the state and federal levels to increase communication and help assure that services to people with disabilities are delivered effectively.

SOURCE California State Independent Living Council

Immunovaccine Announces Financial Results for the Quarter Ended March 31, 2012

Thu, 24 May 2012 20:05:00 +0000

- New vaccine collaborations in infectious diseases and cocaine addiction validate the promise of Immunovaccine's technologies

- Successful private placement raises $2.8 million

Immunovaccine Inc. (TSX VENTURE:IMV) ("Immunovaccine" or the "Company"), a clinical stage vaccine company developing the patented DepoVax^â¢ vaccine adjuvanting platform and product candidates for cancer therapy and infectious diseases, today released its financial and operational results for the quarter ended March 31, 2012.

John Trizzino, CEO of Immunovaccine, commented,

"Since the beginning of 2012, we have entered into three new collaborative agreements with world leading organizations for the purpose of developing vaccines to address cocaine addiction, bio-defense threats and the fast-growing companion animal market. We believe this traction provides validation of both our technology and development strategy. In order to sustain our momentum, we successfully completed a private financing during the period raising approximately $2.8 million. By any measure, the first quarter of 2012 has been a time of significant progress for Immunovaccine."

Highlights of the First Quarter 2012:

Continued to enroll and vaccinate patients in DPX-Survivac Phase I clinical trial. The ongoing Phase I trial is an open label clinical trial designed to evaluate sequentially the safety of two DPX-Survivac dosing regimens in approximately 15 patients. The goal of the Phase I clinical trial is to establish the safety and immune activity of DPX-Survivac in patients with advanced ovarian cancer.

Raised gross proceeds of approximately $2.8 million through a non-brokered private placement on March 7, 2012. Immunovaccine issued 9,294,005 common shares at the price of $0.30 per common share.

Signed a research agreement with Weill Cornell Medical College to advance a vaccine for treating cocaine addiction. The project will combine Cornell's novel cocaine antigen with Immunovaccine's DepoVax adjuvanting platform to strengthen the immune response shown in research animals in previous studies at the College.

Entered into a research collaboration to develop next generation bio-defense vaccines against the most threatening biological agents. These novel vaccine candidates will be evaluated as part of a US National Institutes of Health (NIH) funded study, initiated in the first quarter of 2012.

Highlights Subsequent to First Quarter End:

Entered into a research collaboration with one of the world's leading animal health companies to develop next generation companion animal vaccines. The resulting vaccine products, which are expected to deliver long-lasting, single-dose protection against infectious diseases in dogs and cats, will be advanced through veterinary studies in several indications by Immunovaccine's research partner.

Announced that biotech investment banker, Stephanie LÃ©ouzon, is being nominated to join Immunovaccine's board. Ms. LÃ©ouzon is a Senior Advisor to Torreya Partners, a New York-based life science advisory firm, and was formerly a Senior Advisor and Managing Director in Health Care Investment Banking at Credit Suisse in London.

Received the "Best Early-Stage Vaccine Biotech" award at the 5th Vaccine Industry Excellence (ViE) Awards ceremony during the World Vaccine Congress Washington 2012 in Washington, D.C. The annual ViE Awards honor the efforts, accomplishments and positive contributions of companies and individuals within the vaccine industry. The "Best Early-Stage Vaccine Biotech" was awarded to Immunovaccine based on the Company's strong early clinical trial results in immunotherapy and key collaborations that have the potential to expand its product pipeline in infectious diseases, addiction and bio-defense vaccines.

Q1 2012 Financial Results

The Company prepares its unaudited interim condensed consolidated financial statements in accordance with Canadian generally accepted accounting principles as set out in the Handbook of the Canadian Institute of Chartered Accountants - Part I ("CICA Handbook"), which incorporates International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

The Company's net loss for the period decreased from a loss of $1.9 million during the quarter ended March 31, 2011 to a loss of $1.4 million during the quarter ended March 31, 2012. This decrease is due mainly to the $698,000 decrease in research and development costs and the $16,000 decrease in business development costs, offset by an increase of $225,000 in general and administrative expenses and an increase of $15,000 in accreted interest.

As of March 31, 2012, Immunovaccine had cash and cash equivalents of $6.5 million and working capital of $6.6 million as compared to $5.1 million in both cash and working capital at December 31, 2011. For the quarter ended March 31, 2012, the company's "cash burn rate" (defined as net loss for the period adjusted for non-cash transactions including amortization, accretion of long-term debt and adjustments, stock-based compensation and shares issued for professional services), was approximately $1.09 million. Management believes this provides the Company with sufficient funds to execute the strategy of completing the Phase I trial of DPX-Survivac, executing business development efforts and pre-clinical collaborations on infectious diseases, while maintaining adequate working capital for the next twelve months.

As of April 19, 2012, the number of issued and outstanding common shares was 63,505,152. On March 31, 2012, the number of stock options outstanding was 5,097,150 and the number of outstanding warrants was 4,137,556.

Immunovaccine's unaudited interim condensed consolidated financial statements for March 31, 2012, filed in accordance with IFRS, and the management discussion and analysis (MD&A), are available at www.sedar.com.

About Immunovaccine

Immunovaccine Inc. applies its novel vaccine delivery platform to the development of vaccines for cancer therapy and infectious disease. The company's DepoVaxâ¢ platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses. Immunovaccine has advanced its platform technology and proprietary cancer vaccine into Phase I human clinical trials and has demonstrated both safety and immunogenicity potential. The Company is also capitalizing on the broad potential of its delivery platform by creating new DepoVax-based vaccines through multiple development collaborations. In addition to the Company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has several key partnerships in the animal health sector including an agreement with Pfizer Animal Health, which has licensed the Company's delivery technology platform to develop vaccines for livestock. Connect at www.imvaccine.com.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.

Immunovaccine Inc.
Kimberly Stephens
CFO
(902) 492-1819
info@imvaccine.com
www.imvaccine.com
Vida Communication (media)
Tim Brons
(415) 675-7402
tbrons@vidacommunication.com
Vida Communication (investors)
Stephanie Diaz
(415) 675-7401
sdiaz@vidacommunication.com

Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains

Thu, 24 May 2012 19:48:58 +0000

Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains

Company will use the Imperial Valley facility to scale up production of algae products including food and nutritional products

SGI will also test microbial fuel cell technology for purification of water from algae processing

PR Newswire

LA JOLLA, Calif., May 24, 2012 /PRNewswire/ -- Synthetic Genomics Inc. (SGI), a privately held company commercializing and developing genomic-driven solutions to solve a range of global challenges, today announced they have purchased an 81 acre site for scale up and testing of newly identified and engineered algal strains. The company will use the site, located in the Imperial Valley near the Salton Sea, to test algal strains isolated by SGI or developed through SGI's proprietary synthetic genomic technologies, and to develop integrated processes for low cost manufacture of various algal products, including food, flavorings, and nutritional products. Results from SGI's new facility will inform the design of future commercial production facilities.

This large site, chosen for its optimal desert environment of little rainfall and plentiful sunshine, has 42 open ponds ranging in size from 100 to 240,000 gallons. The company is also designing and building a range of new closed photobioreactors to test and scale up engineered strains of algae. The site is currently being renovated, with algae production beginning within the next 60 days.

"The Imperial Valley facility is an important step forward for SGI as we will now be able to scale up production of the algae strains that we have isolated, developed and engineered," said J. Craig Venter, Ph.D., Founder and CEO, SGI. "Over the last year SGI has been making steady progress in identifying and modifying a variety of strains capable of producing a broad range of products for all of our algae programs including our food and nutritional products program. The new facility will help us test these strains and production processes in a larger and more real world setting."

SGI is also testing new microbial fuel cell technology to purify and recycle water from the algae processing.

About Synthetic Genomics Inc.
SGI, a privately held company founded in 2005, is dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key research and business programs including: developing algae biofuels in alliance with Exxon Mobil Research and Engineering Company, microbial-enhanced hydrocarbon recovery and conversion through an agreement with BP, new and improved food and nutritional products, and clean water technologies. SGI is also involved in synthetically derived vaccine development through Synthetic Genomic Vaccines Inc. (SGVI), a company co-founded with the J. Craig Venter Institute; and to developing sustainable crops and agricultural products through Agradis Inc., a company co-founded with Plenus S.A. de C.V. For more information go to: www.syntheticgenomics.com.

SGI Media Contact:

Heather Kowalski, hkowalski@syntheticgenomics.com; 858-361-0466

SOURCE Synthetic Genomics Inc.

Industry Leaders Discuss Innovations in Wireless Health Services and Technologies to Improve Consumer Access to Healthcare

Thu, 24 May 2012 18:30:00 +0000

WHO:
The X PRIZE Foundation and Nokia today announced the launch of the Nokia Sensing X CHALLENGE, a $2.25 million global competition to stimulate the development of a new generation of health sensors and sensing technologies that can drastically improve the quality, accuracy and ease of monitoring a person's health. Improvements in these technologies will empower individuals to effortlessly monitor and collect their own real-time health data, providing both consumers and healthcare providers convenient access to critical information whenever and wherever they need it.

WHAT:
Following this announcement, the X PRIZE Foundation will host
Eyes on the Prize: Incentivizing Innovation in Wireless Health, a panel discussion with:

Dr. Peter H. Diamandis, Chairman and CEO, X PRIZE Foundation
Dr. Henry Tirri, Executive Vice President and Chief Technology Officer, Nokia
Dr. Paul E. Jacobs, Chairman and CEO, Qualcomm Incorporated and Chair, Qualcomm Foundation
Eugene 'Rod' Roddenberry, Co-Founder and Board Chair, The Roddenberry Foundation

Moderated by Robert B. McCray, President and CEO, Wireless-Life Sciences Alliance

WHEN:
Thursday, May 24, 2012, 3:30pm - 4:15pm PT

WHERE:
To view the live webcast, please visit www.livestream.com/xprize.

WHY:
The inefficiencies and total cost of the U.S. healthcare system (and healthcare systems around the globe) has been a pressing social and political issue for many years. In the U.S., the total spent annually on the healthcare system is more than $2 trillion, which accounts for more than 15 percent of the nation's gross domestic products. Health sensors have the capacity to stem this trend. Consumer use of mobile devices that utilize sensors and sensing technology has the potential to improve, extend and ease delivery of healthcare services, as well as reduce costs to the benefit of health providers and patients.

For more information about the $2.25 million Nokia Sensing X CHALLENGE and $10 million Qualcomm Tricorder X PRIZE, please visit www.nokiasensingxchallenge.org and www.qualcommtricorderxprize.org.

Biostem U.S., Corporation Announces $5,000,000 Financing Agreement Through Private Placement of Stock

Thu, 24 May 2012 17:59:00 +0000

Biostem U.S., Corporation, (OTCQB: HAIR) (PINKSHEETS: HAIR) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, announces a $5,000,000 financing agreement through private placement of stock.

CEO, Dwight Brunoehler, announced today that the company has signed an agreement with a funder to issue 20,000,000 shares of the company's common stock in exchange for $5,000,000 in cash or 25 cents ($.25) per share. No other considerations will be granted to the funder in exchange for the cash payment.

In announcing the funding agreement, Mr. Brunoehler commented, "We consider the eagerness of the funder to acquire Biostem shares at a price above the current market to be a tribute to our proven proprietary technology to enhance hair re-growth using human stem cells. Although we anticipated funding the company through the sale of a convertible debenture, the funder insisted on being able to acquire stock at a set price now, rather than risk having to convert at higher prices later. Although Rule 144 sale restrictions usually cause private placements of stock to be executed at a discount to the market, Biostem feels that its current share price is not truly reflective of the value of its proprietary technology; as well as the fact that the technology is already being employed, and the overall size of the hair replacement marketplace. It was for this reason that the company and the funder were able to come to an agreement to price the private placement above the current share price."

About Biostem U.S., Corporation

Biostem U.S., Corporation is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered on providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.

More information on Biostem U.S., Corporation can be obtained through www.biostemus.com, or by calling Fox Communications Group 310-974-6821.

Contact:
Fox Communications Group
310-974-6821

Nokia Sensing X CHALLENGE -- Searching the World for the Most Powerful Digital Health Sensors to Transform the Healthcare Industry

Thu, 24 May 2012 17:11:00 +0000

X PRIZE Foundation and Nokia Introduce $2.25 Million Global Incentivized Competition to Bring About Entirely New Ways to Monitor, Access, and Improve Consumer Health

The X PRIZE Foundation and Nokia today announced the launch of the Nokia Sensing X CHALLENGE, a $2.25 million global competition to stimulate the development of a new generation of health sensors and sensing technologies that can drastically improve the quality, accuracy and ease of monitoring a person's health. Improvements in these technologies will empower individuals to effortlessly monitor and collect their own real-time health data, providing both consumers and healthcare providers convenient access to critical information whenever and wherever they need it.

The announcement was made by X PRIZE Foundation Chairman and CEO Dr. Peter H. Diamandis and Nokia Executive Vice President and Chief Technology Officer Dr. Henry Tirri during their keynote address at the Wireless Health Convergence Summit in San Diego, Calif.

"Partnering with Nokia is a natural fit for this competition. Health sensing technologies enabled by artificial intelligence, lab-on-a-chip, and digital imaging are advancing exponentially and will ultimately integrate with your phone. We need to expand sensor and sensing technology beyond disease management to areas such as public health and fitness," said Dr. Diamandis. "The Nokia Sensing X CHALLENGE will bring about radical innovation in health sensors and sensing technologies, which paves the way for better choices in when, where, and how individuals receive care. Ultimately, healthcare will be more convenient, affordable, and accessible to consumers worldwide through these integrated digital health solutions."

The inefficiencies and total cost of the U.S. healthcare system (and healthcare systems around the globe) has been a pressing social and political issue for many years. In the U.S., the total spent annually on the healthcare system is more than $2 trillion1, which accounts for more than 15 percent of the nation's gross domestic product. Health sensors have the capacity to stem this trend. Consumer use of sensors and sensing solutions has the potential to improve, extend and ease delivery of healthcare services, as well as reduce costs to the benefit of health providers and patients.

"Nokia engages in Open Innovation on many different levels; this type of 'grand challenge' is not only a unique method of driving significant progress in a short space of time, but one which can also help to create an entire ecosystem," said Dr. Tirri. "This competition will enable us to realize the full potential of mobile sensing devices, leading to advances in sensing technology, which can play a major role in transforming the lives of billions of people around the world."

The Nokia Sensing X CHALLENGE will be a series of three competition events, held over the next three years. Each event will be comprised of three phases: Registration, Preliminary Judging and Final Phase Judging. The winners of each competition will be the teams that submit best in class technology as determined by a non-partisan judging panel of cross-functional industry experts.

It is anticipated that the solutions developed as part of the Nokia Sensing X CHALLENGE may also be utilized as part of a team's effort to win the $10 million Qualcomm Tricorder X PRIZE, which was announced at the 2012 Consumer Electronics Show (CES) during Qualcomm Incorporated Chairman and CEO and Qualcomm Foundation Chair Dr. Paul Jacobs' keynote address. The Qualcomm Tricorder X PRIZE is a global competition aiming to drive development of devices that allow consumers access to healthcare in the palm of their hands. The Nokia Sensing X CHALLENGE and Qualcomm Tricorder X PRIZE will help create an ecosystem of innovators and innovative technology that will help reinvent the healthcare industry and radically reduce the cost to consumers.

For more information about the Nokia Sensing X CHALLENGE, visit: nokiasensingxchallenge.org.

About X PRIZE Foundation
Founded in 1995, the X PRIZE Foundation, a 501(c)(3) nonprofit, is the leading organization solving the world's Grand Challenges by creating and managing large-scale, high-profile, incentivized prize competitions that stimulate investment in research and development worth far more than the prize itself. The organization motivates and inspires brilliant innovators from all disciplines to leverage their intellectual and financial capital for the benefit of humanity. The X PRIZE Foundation conducts competitions in five Prize Groups: Education; Exploration; Energy & Environment; Global Development; and Life Sciences. Active prizes include the $30 million Google Lunar X PRIZE, the $10 million Archon Genomics X PRIZE presented by Express Scripts, the $10 million Qualcomm Tricorder X PRIZE, and the $2.25 million Nokia Sensing X CHALLENGE. For more information, go to www.xprize.org.

About Nokia
Nokia is a global leader in mobile communications whose products have become an integral part of the lives of people around the world. Every day, more than 1.3 billion people use their Nokia to capture and share experiences, access information, find their way or simply to speak to one another. Nokia's technological and design innovations have made its brand one of the most recognized in the world. For more information, visit http://www.nokia.com/about-nokia.

Social Tags:

Facebook: Nokia Sensing X CHALLENGE
Twitter: @NokiaXCHALLENGE, hashtag: #sensing

TRICORDER is a trademark of CBS Studios, Inc. used under license. Qualcomm is a registered trademark of Qualcomm Incorporated. All other trademarks are the property of their respective owners.

1Centers for Medicare & Medicaid Services, Office of the Actuary, National Health Statistics Group; U.S. Department of Commerce, Bureau of Economic Analysis; and U.S. Bureau of the Census. Retrieved from https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/downloads//tables.pdf

X PRIZE Foundation Chairman and CEO Dr. Peter H. Diamandis and Nokia Executive Vice President and Chief Technology Officer Dr. Henry Tirri announced the launch of the Nokia Sensing X CHALLENGE at the Wireless Health Convergence Summit in San Diego, Calif.

True Diagnostics Receives CE Mark for TrueDX(TM) Platform & TSH Test

Thu, 24 May 2012 16:52:00 +0000

True Diagnostics, Inc.™ (www.TrueDiagnostics.com) has announced it has received a CE Mark to allow it to distribute its TrueDX Platform and quantitative TSH (Thyroid Stimulating Hormone) test in Europe. With the TrueDX Platform, doctors can immediately determine if a patient suffers from a hypoactive thyroid by using only a finger prick of blood. This unique test enables doctors and patients to gain access to diagnosis in minutes, create an effective treatment plan, while saving physicians' time and patients cost and anxiety. True Diagnostics is actively engaging distribution partners throughout all EU markets, with initial focus in Germany, UK, France, Italy and Spain.

This is the second regulatory clearance for the TrueDX Platform with TSH test, having received sFDA approval for China in September 2011. True Diagnostics expects to run short clinical studies in the U.S. this summer and further submit for CLIA-waive and 510k FDA clearance to market the TrueDX Platform with quantitative TrueDX-TSH™ Tests throughout the U.S.

What will the TrueDX Platform mean for doctors and patients seeking to more easily identify Hypoactive Thyroid? Hypothyroidism affects over 200 million people globally, more than people with diabetes. TSH is the fourth most requested blood test in America. Hypothyroidism is commonly undiagnosed and misdiagnosed with symptoms ranging from weight gain to depression, forgetfulness, hair loss, thinning and drying of skin, fatigue, loss of libido, feeling cold, constipation, and a pronounced goiter.

Jerry Lee, President/CEO of True Diagnostics, notes, "With this latest regulatory clearance, the Company has laid the foundation to begin standardizing a full range of diagnostic and monitoring tests that will provide instant results to doctors and patients and demand little training. With distribution partners already lined up and more coming soon, we expect initial shipments to Europe to begin within 60 days."

The strength of the TrueDX Platform lies in its simplicity. Tests have a 24-month shelf life. They do not need to be refrigerated. Laboratory quality results from small samples can now be available to doctors to review in minutes. The TrueDX Platform's simplicity, portability, and affordability allow it to be easily adopted into emerging markets. The platform's flexible design also permits it to stay ahead of potential competitors and quickly commercialize a myriad of new biomarkers discoveries for cancer, autism, alzheimer's, diabetes, drugs of abuse, infectious diseases, cardiac health, traumatic brain injury, viral and bacterial infections, and more. In essence, any biomarker discovery utilizing traditional lab methods, such as an ELISA process, can now be developed into a simple, fast, and portable assay which can offer quick diagnosis and treatment right in the physician's office.

About the Company
True Diagnostics, Inc. creates simple diagnostic solutions for the $46 billion medical point-of-care, sterility assurance, animal health, and food processing markets. After 30 years in the global medical diagnostic field, the inventor of the home pregnancy test created the TrueDX Platform which can measure the severity of any medical condition (using only a finger prick of blood, small urine or saliva sample, toxins, surface bacteria, and more), provide results in minutes (not days), and is completely portable. The TrueDX Platform takes point-of-care, point-of-incidence, and remote-of-care applications out of the lab to provide more flexible treatment that can begin immediately. The TrueDX Platform creates unique and powerful opportunities for new diagnostic solutions through its ability to: 1) quickly bring new diagnostic tests to market; and, 2) open new geographic and application opportunities.

For more information, call 760-683-9158 or go to www.TrueDiagnostics.com

Contact:
Jerry Lee
President/CEO
Email Contact

TrueDX Platform with Reader, TSH Test kit and PC Software.

Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock

Thu, 24 May 2012 16:00:00 +0000

Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock

PR Newswire

SAN DIEGO, May 24, 2012 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing and commercializing targeted rescue therapies for patients in acute ischemic crisis, today announced that it recently received $50 million in additional equity funding from existing investor, Leucadia National Corporation. This funding was made upon the exercise of Series G preferred stock warrants previously held by Leucadia and brings the total funding raised by the company since inception to more than $280 million.

(Logo: http://photos.prnewswire.com/prnh/20120524/LA12228LOGO)

This funding followed an independent Data Monitoring Committee (DMC) review of safety data from the first 122 patients enrolled in the Phase 2b trauma study involving MP4OX, Sangart's novel oxygen therapeutic agent (OTA) developed to perfuse and oxygenate tissues at risk for ischemia in patients experiencing hemorrhagic shock. After evaluating the data, the DMC unanimously recommended that the study should continue without any modification.

"We are encouraged by this level of support from our existing investors, who recognize the clinical potential of our products," said Brian O'Callaghan, President and CEO of Sangart. "This funding will allow us to continue advancing the development of our medicines and get them as quickly as possible to patients in need. We continue to see promise in our unique MP4 gas-delivery platform, focused on developing therapies for patients in crisis who are experiencing ischemia and organ dysfunction as a result of hemorrhagic shock injury or a vaso-occlusive crisis associated with sickle cell disease."

The funds will be used to advance the development of the MP4OX product in severe traumatic hemorrhagic shock and the MP4CO product in sickle cell disease.

About MP4
Sangart's unique MP4 gas-delivery platform is being used to develop therapies for patients in crisis who are experiencing ischemia (oxygen deprivation of tissues) and organ dysfunction as a result of hemorrhagic shock injury or a vaso-occlusive crisis associated with sickle cell disease.

About Sangart
Sangart is a global biopharmaceutical company dedicated to developing and commercializing targeted rescue therapies for patients in acute ischemic crisis. Sangart's therapies are designed to help patients with medical conditions that cause ischemia, such as hemorrhagic shock and sickle cell disease.

To learn more about Sangart, please visit the company's website at www.sangart.com.

Media Contact:
Vivian Cabral
Edelman Public Relations
Office: 323-202-1032
vivian.cabral@edelman.com

SOURCE Sangart, Inc.

College Chairman And Prolific Inventor Develops Life-Saving, Real-Time Diagnostic Technologies

Thu, 24 May 2012 15:59:22 +0000

College Chairman And Prolific Inventor Develops Life-Saving, Real-Time Diagnostic Technologies

Donald Spector Says a Simple Smartphone Can Change the Face of Medicine

PR Newswire

NEW YORK, May 24, 2012 /PRNewswire/ -- For years, doctors and microbiologists have sent out biopsies, slides, X-rays and other information outside the body for examination. These tests take days to get back and cannot be used immediately or during procedures. Donald Spector, a well-known, serial entrepreneur-inventor and Chairman of New York College of Health Professions, one of the few institutionally accredited schools of Acupuncture and Massage Therapy in the nation, is changing the face of medicine. Spector is developing a patent that makes it possible to connect everything from powerful scopes used in diagnosis and surgery to computers that can enhance the images, match databases in real time and provide real-time information to doctors during procedures or operations.

Over thirty years ago, Spector emerged as an inventor, developing products over the years that have opened up billion dollar industries. Known in his earlier days for inventions such as the hydraulic exerciser and the first hyperbaric chamber for plants, Spector went on to develop the Aroma Disc System with the Squibb Corporation, which transformed the world of aromatherapy in the 1980's from deodorizers to mood creations. Over a decade ago, he developed patents for location based advertising, which today are the cornerstone technology for Poynt, one of the largest applications in the world.

While computer technologies represent only about ten percent of Spector's vast portfolio of patents, trademarks and copyrights, they represent a major part of his and New York College of Health Professions' future, and his latest patent for medical technologies will provide doctors around the world a revolutionary and powerful diagnostic tool on the cutting edge of the next frontier in surgery: connectivity.

"In certain instances, we don't even need high-powered scopes," stated Spector. "A simple smartphone with a few megapixels can be used to photograph, enhance, match databases and provide real-time information on moles or sunspots to patients and physicians. While this is not a replacement for the physician, it prompts patients to visit physicians in a timely manner and encourages early diagnosis, bringing peace of mind in seconds. In the future, surgeons will not have to wait for an MRI to tell them that all malignant cells were removed – they will know instantly."

Spector's patent is only one of numerous computer-enhanced medical technologies that will change the face of medicine, not only at the great university centers around the world, but in remote geographic areas, where computers, optical equipment and database matching will be able to identify bacteria, viruses and disease in real time. Several famous doctors and hospital leaders are working to help the College, which is also introducing new technologies patented by Spector in LED's that can kill super bacteria and cleanse wounds, as well as reduce contagion.

Barbara Carver, Senior Vice President of Marketing for New York College of Health Professions and a former colleague of Spector's at the Squibb Corporation, commented, "Ironically, when the Aroma Disc was launched in 1984 as the 'Next Frontier in Home Entertainment', everyone made reference to 'Big Brother' of the Huxley novel, 1984. Today, our products are more advanced than science fiction. While some of these products are too big for our small institution, New York College of Health Professions will be forming research collaborations with other universities, as well as spinning off private companies, which will once again be working with Fortune 500 companies. We can't wait to change the future of medicine on a global scale."

ABOUT NEW YORK COLLEGE OF HEALTH PROFESSIONS
Chartered by the New York State Board of Regents, New York College of Health Professions, a not-for-profit institution located in Syosset, Long Island, with three additional sites in New York City, offers institutionally accredited undergraduate and graduate-level degree programs in Massage Therapy, Acupuncture, Oriental Medicine and Herbal Medicine, and Certificate programs in Holistic Nursing for Registered Nurses and The Science of Self Improvement. New York College maintains a 30-acre modern medical facility in Luo Yang, The People's Republic of China. The College has grown remarkably in the past several years and will continue to develop new educational programs as well as expand into many new areas. For more information about New York College of Health Professions visit www.NYCollege.edu.

NEW YORK COLLEGE OF HEALTH PROFESSIONS
6801 Jericho Turnpike
Syosset, New York
www.NYCollege.edu

Rubenstein Public Relations
Jennifer Seley, 212.843.8295
Email: jseley@rubensteinpr.com

SOURCE New York College of Health Professions

Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference

Thu, 24 May 2012 15:58:22 +0000

Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference

PR Newswire

ANAHEIM, Calif., May 24, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Jefferies 2012 Global Healthcare Conference in New York on June 6, 2012 at 5:00 a.m. PT / 8:00 a.m. ET.

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also currently preparing to launch a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Lupus, Dermatomyositis, Polymyositis and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.

China Integrated Energy Inc. Completes Independent Investigation

Thu, 24 May 2012 14:00:46 +0000

China Integrated Energy Inc. Completes Independent Investigation

PR Newswire

XI'AN, China, May 24, 2012 /PRNewswire-Asia/ -- China Integrated Energy, Inc. (OTC Pink: CBEH) ("China Integrated Energy" or the "Company"), a leading non-state-owned integrated energy company in the People's Republic of China, today announced the completion of the thorough Independent Investigation conducted by the Audit Committee into allegations raised in reports published in early 2011. Although the specific findings and conclusions of the Committee, as advised by its legal and forensic accounting professionals, remain privileged, the Company announced that the Committee has informed it that the Committee is satisfied that the vast majority of the short sellers' claims were baseless. Based on its investigation, however, the Committee has made observations, primarily regarding strengthening internal controls, which the Company will actively pursue.

Beginning in March 2011, short sellers calling themselves Sinclair Upton and Alfred Little published claims that China Integrated had made misrepresentations or other alleged wrongdoing regarding (1) cash in the bank, (2) related party transactions allegedly benefitting the Company's Chairman and his family, (3) the Company's overall financial health, as demonstrated by differences between Chinese filings with the SAIC and US filings with the SEC, (4) certain accounting practices, (5) the value and ownership of gas stations owned or leased by the Company, (6) the Company's affiliations with educational and research institutions, (7) the Company's auditors, (8) whether the Company enjoyed certain tax exemptions, (9) the Company's licenses , (10) the VIE structure, (11) the Company's wholesale distribution network, and (12) the Company's production of biodiesel.

In May 2011, the Audit Committee engaged Shearman & Sterling LLP to lead the independent investigation into these allegations. Each of these allegations was thoroughly investigated. While some issues remain as to production at the Company's Tongchuan biodiesel facility, and while the investigation revealed the need to strengthen internal controls and take similar measures, the primary substance of all other allegations has been proven groundless. Sales of biodiesel accounted for approximately 17% of the Company's revenue in FY2010. The Committee applauded the Company for its full cooperation given throughout the investigation.

Speaking on behalf of the Company, its Chairman, Xincheng Gao, stated: "We are heartened, but not surprised, to hear the Audit Committee's conclusions. From the day the short sellers issued their attacks, we have consistently and vehemently denied them. Unfortunately, in this climate, people like the short sellers can say anything and then it is up to the Company to prove its innocence. While we are happy that we have been able to do so, the effort has cost the Company, and therefore its shareholders, a great deal. We are of course struck by the fact that the short sellers accused us of making false statements to benefit ourselves financially, when, in fact, that is precisely what the short sellers did. We will continue to defend ourselves and also continue to work with the Audit Committee to resolve any remaining issues regarding biodiesel production. We also appreciate that this thorough evaluative process inevitably and productively leads to useful recommendations, which will make our Company stronger and even more responsive to the interests of its shareholders."

About China Integrated Energy, Inc.

China Integrated Energy, Inc. is a leading non-state-owned integrated energy company in China engaged in three business segments: the production and sale of biodiesel, the wholesale distribution of finished oil and heavy oil products, and the operation of nine retail gas stations. The Company operates biodiesel production capacity within two plants located in Tongchuan, Shaanxi province, and one plant in Chongqing, China. The Company utilizes a distribution network covering 16 provinces and municipalities, established over the past 11 years, to distribute both heavy oil and finished oil, including gasoline, petro-diesel, and biodiesel. For additional information on the Company, please visit http://www.chinaintegratedenergy.com.

An online investor kit including a company presentation, news releases, price quotes, stock charts, and other valuable information for investors is available at http://www.chinaintegratedenergy.com. To subscribe to future releases via e-mail alert, visit http://www.chinaintegratedenergy.com/alerts

Safe harbor statement

This news release includes statements that may constitute forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. For example, statements about the future use of the proceeds are forward looking and subject to risks. China Integrated Energy, Inc., may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission on forms 10-K, 10-Q, and 8-K in its annual report to shareholders, in news releases and other written materials and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to, risks outlined in the Company's filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement, except as required under law.

For more information, please contact:

China Integrated Energy, Inc.
Roger Zheng
Investor Relations
Tel: +86-29-68592316
Email: zx@cbeh.net.cn
Web: www.chinaintegratedenergy.com

Christensen
Mr. Chen Yuanyuan (English and Chinese)
Mobile +86 139 2337 7882 in China
ychen@christensenir.com

Mr. Tom Myers (English)
Mobile +86 139 1141 3520 in Beijing
tmyers@christensenir.com

SOURCE China Integrated Energy, Inc.